Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

US6849636B2 · kind B2 · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• Sherman T. Waddell · Westfield, US
• Gina M. Santorelli · Long Branch, US
• Milana Maletic · Summit, US
• Aaron H. Leeman · Cranford, US
• Xin Gu · Scotch Plains, US
• Donald W. Graham · Mountainside, US
• James M. Balkovec · North Plainfield, US
• Susan D. Aster · Teaneck, US

Key dates

• Filing date: Dec 18, 2003
• Grant date: Feb 1, 2005
• Expiry date: Dec 18, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.